Cooley advised Lantheus Holdings (LNTH on Nasdaq) on its strategic transactions with Perspective Therapeutics (CATX on NYSE American), which consists of an agreement to purchase up to a 19.99% stake in Perspective through a private investment in public equity (PIPE) transaction, Perspective’s grant to Lantheus of options to exclusively license and/or co-develop certain of Perspective’s therapeutic candidates, and Perspective’s agreement to acquire a manufacturing facility and related assets from Lantheus.